A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

LESSONS LEARNED. Ofatumumab infusion reactions can be diminished by escalating the dose rate in individual patients in sequential infusions. BACKGROUND. Ofatumumab (OFA) is a fully humanized, anti‐CD20 antibody approved for use in chronic lymphocytic leukemia (CLL). The recommended administration re...

Descripción completa

Detalles Bibliográficos
Autores principales: Donnellan, William, Berdeja, Jesus G., Shipley, Diana, Arrowsmith, Edward R., Wright, David, Lunin, Scott, Brown, Richard, Essell, James H., Flinn, Ian W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634770/
https://www.ncbi.nlm.nih.gov/pubmed/28687625
http://dx.doi.org/10.1634/theoncologist.2017-0236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634770/
https://www.ncbi.nlm.nih.gov/pubmed/28687625
http://dx.doi.org/10.1634/theoncologist.2017-0236

Ejemplares similares